Poly (ADP-Ribose) Polymerase-1
"Poly (ADP-Ribose) Polymerase-1" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A poly(ADP-ribose) polymerase that contains two ZINC FINGERS in its N-terminal DNA-binding region. It modifies NUCLEAR PROTEINS involved in chromatin architecture and BASE EXCISION REPAIR with POLY ADENOSINE DIPHOSPHATE RIBOSE.
| Descriptor ID |
D000071137
|
| MeSH Number(s) |
D08.811.913.400.725.115.690.420
|
| Concept/Terms |
Poly (ADP-Ribose) Polymerase-1- Poly (ADP-Ribose) Polymerase-1
- Poly (ADP-Ribose) Synthase-1
- PARP1 Protein
- PARP-1 Protein
- PARP 1 Protein
- NAD+ ADP-ribosyltransferase-1
- NAD+ ADP ribosyltransferase 1
|
Below are MeSH descriptors whose meaning is more general than "Poly (ADP-Ribose) Polymerase-1".
Below are MeSH descriptors whose meaning is more specific than "Poly (ADP-Ribose) Polymerase-1".
This graph shows the total number of publications written about "Poly (ADP-Ribose) Polymerase-1" by people in this website by year, and whether "Poly (ADP-Ribose) Polymerase-1" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2016 | 1 | 1 | 2 |
| 2017 | 3 | 2 | 5 |
| 2018 | 3 | 3 | 6 |
| 2020 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Poly (ADP-Ribose) Polymerase-1" by people in Profiles.
-
SARS-CoV-2: Understanding the Transcriptional Regulation of ACE2 and TMPRSS2 and the Role of Single Nucleotide Polymorphism (SNP) at Codon 72 of p53 in the Innate Immune Response against Virus Infection. Int J Mol Sci. 2021 Aug 12; 22(16).
-
The Molecular Basis of COVID-19 Pathogenesis, Conventional and Nanomedicine Therapy. Int J Mol Sci. 2021 May 21; 22(11).
-
Immune-Modulating Drug MP1032 with SARS-CoV-2 Antiviral Activity In Vitro: A potential Multi-Target Approach for Prevention and Early Intervention Treatment of COVID-19. Int J Mol Sci. 2020 Nov 20; 21(22).
-
Poly(ADP-Ribose) Polymerase Inhibition in Acute Lung Injury. A Reemerging Concept. Am J Respir Cell Mol Biol. 2020 11; 63(5):571-590.
-
Immunotherapy of COVID-19 with poly (ADP-ribose) polymerase inhibitors: starting with nicotinamide. Biosci Rep. 2020 10 30; 40(10).
-
Characterization of the cytokine storm reflects hyperinflammatory endothelial dysfunction in COVID-19. J Allergy Clin Immunol. 2021 01; 147(1):107-111.
-
PARP-inhibitors in a non-oncological indication as COVID-19: Are we aware about its potential role as anti-thrombotic drugs? The discussion is open. Biomed Pharmacother. 2020 Oct; 130:110536.
-
Influence of NAD+ as an ageing-related immunomodulator on COVID 19 infection: A hypothesis. J Infect Public Health. 2020 Sep; 13(9):1196-1201.
-
Mycoplasma promotes malignant transformation in vivo, and its DnaK, a bacterial chaperone protein, has broad oncogenic properties. Proc Natl Acad Sci U S A. 2018 12 18; 115(51):E12005-E12014.
-
Mechanisms for stalled replication fork stabilization: new targets for synthetic lethality strategies in cancer treatments. EMBO Rep. 2018 09; 19(9).